Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Inclusion, innovation, and belonging
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Organon Partners with Kuwait Pharmacy Association to advance women’s health and community pharmacy services in Kuwait

Save Print

May 30, 2025 7:18 am EDT

  • MoU signed to empower pharmacists and enhance patient care through educational and awareness initiatives
  • Launch of Pharmacy Training Program to focus on enhancing women’s health services and drive patient-centred community care

Kuwait City, Kuwait – April 24, 2025 – Organon, a global healthcare company dedicated to improving women’s health, announced the signing of a Memorandum of Understanding (MoU) with the Kuwait Pharmacy Association (KPA), the professional body representing pharmacists in Kuwait. The collaboration aims to advance women’s health and strengthen the role of community pharmacists in delivering high-quality patient-centered care across the country.

The MoU was signed during Kuwait Pharmaceutical Advancement Conference & Exhibition (KPAC) by Dr. Ahmad Taqi, President of the Kuwait Pharmacy Association, and Ahmed Lasheen, Kuwait, Bahrain and Qatar Lead at Organon, in the presence of [please add if there are any other ].

The partnership between Organon and the KPA launches with the “Excellence in Patient Care inside the Pharmacy” training program, designed to strengthen the role of community pharmacists in advancing women’s health—particularly in the area of family planning. The program aims to equip pharmacists with enhanced skills in patient communication, pharmacy operations, and the use of AI tools, ensuring they are well-prepared to deliver high-quality, accessible healthcare services. By empowering pharmacists as front-line health advisors, this initiative will help expand access to essential women’s health services across communities in Kuwait.

Delivered through both in-person and online training, the program places strong emphasis on enabling pharmacists to offer informed, empathetic counseling to women around reproductive health and family planning. Additional training will cover areas such as pain management and respiratory care, reinforcing the pharmacist’s evolving role as a key healthcare provider within the community. This collaboration reflects a shared commitment to supporting healthier families and fostering a more resilient society through stronger, community-based care.

Ahmed Lasheen, Country Lead for Kuwait, at Organon, commented: “This partnership with the Kuwait Pharmacy Association aligns with Organon’s mission to improve women’s health and empower healthcare professionals. By investing in education and training for pharmacists, we aim to create a stronger foundation for delivering better patient care and addressing key aspects of women’s health in order to foster healthier communities. We are proud to support this important collaboration as part of our broader commitment to advancing women’s healthcare across the region .”

Dr. Ahmad Taqi, President of the Kuwait Pharmacy Association, added: “We are pleased to partner with Organon to enhance the role of pharmacists as frontline healthcare providers. Our shared goal is to elevate the standard of care delivered in pharmacies across Kuwait and ensure that pharmacists are well-equipped with the latest knowledge and tools. This collaboration is a step toward achieving our mission of innovation, empowerment, and excellence in pharmaceutical care, fostering greater accessibility to healthcare and supporting healthier communities.” This collaboration reflects Organon’s commitment to advance women’s health across the region by forging strategic partnerships and supporting the development of a more equitable healthcare environment for women and families.

What can we help you find?

Search for:
META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept